Trial reportClinical pharmacokinetics2003
Pharmacokinetics of intravenous and rectal ketoprofen in young children.
Trial report in Clinical pharmacokinetics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Antipyretic effect of ketoprofen.Indian journal of pediatrics · 2009Trial
- Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.Clinical pharmacokinetics · 2004Trial
- Optimizing Pediatric Drug Therapy: Pediatric Pharmacokinetics and Administration Routes.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Intravenously Administered Nonsteroidal Anti-Inflammatory Drugs in Clinical Practice: A Narrative Review.Pharmacy (Basel, Switzerland) · 2025Review
- Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.Paediatric drugs · 2022Review
- Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo.Science advances · 2020Article
- Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.AAPS PharmSciTech · 2014Article
- Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults.Pharmaceutics · 2011Article
- Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients.Paediatric drugs · 2010Review
- Ketoprofen produces modality-specific inhibition of pain behaviors in rats after plantar incision.Anesthesia and analgesia · 2009Article
- Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.Clinical pharmacokinetics · 2006Review
- Nonopioid analgesics for perioperative and cardiac surgery pain in children: Current evidence and knowledge gaps.Annals of pediatric cardiologyReview
- Diclofenac and ketoprofen liver toxicity in rat.European journal of drug metabolism and pharmacokineticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the relative bioavailabilities of ketoprofen after intravenous and rectal administration to young children.
designOpen-label prospective parallel-group study. PATIENTS: Participants were 28 children aged 7 to 93 months.
methodsEighteen children received a single intravenous injection of ketoprofen 1 mg/kg, and ten children, weight 16-24 kg, received a 25mg ketoprofen suppository. Venous blood samples were collected at selected times after administration, ranging from 2 minutes to 8 hours for the intravenous group and from 30 minutes to 8 hours for the suppository group. A validated high performance liquid chromatography method was used to measure plasma ketoprofen concentrations.
resultsIn the intravenous group, the maximum plasma concentration of ketoprofen ranged between 10.5 and 22.2 mg/L, and in the suppository group, following dose normalisation to 1 mg/kg of ketoprofen, between 3.8 and 7.4 mg/L. In the intravenous group, area under the concentration-time curve from zero to infinity ranged between 9.2 and 23.5 mg x h/L, and in the suppository group after dose normalisation between 8.8 and 12.9 mg x h/L. The bioavailability of ketoprofen from the suppository was about 73%. Volume of distribution was 0.04-0.10 L/kg in the intravenous group and 0.08-0.16 L/kg in the suppository group. The terminal half-life was comparable in both study groups, ranging between 0.7 and 3.0 hours in the intravenous group and between 1.2 and 2.9 hours in the suppository group.
conclusionAbsorption of ketoprofen after rectal administration is reasonably rapid and predictable. Because the bioavailability of rectal ketoprofen is also relatively high, a suppository may be used in children in whom the drug cannot be given intravenously or by mouth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.